PharmiWeb.com - Global Pharma News & Resources
06-Dec-2021

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Cambridge, England, 6 December 2021 - Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Martin Pass, as Chief Development Officer (CDO).

Martin joins Amphista from AstraZeneca, where he was Vice President, Head Early Oncology Projects and led successful clinical development efforts. Martin has over 30 years’ experience in the pharmaceutical industry with many successes spanning early drug discovery through to Phase 3 clinical development.

 

Previously, Martin was a medicinal chemist at GlaxoSmithKline where he helped progress multiple candidates into clinical development in the cardiovascular, CNS and gastrointestinal therapeutic areas. He has a PhD in Organic Chemistry from Imperial College London and worked in post-doctoral research at the University of Virginia, USA. He is a co-author on over 60 patents and peer-reviewed publications.

 

Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team, I am delighted to welcome Martin as our CDO. Martin brings a wealth of strategic clinical development expertise from an impressive global career as a leader in clinical trials, in two world leading pharmaceutical companies. Martin’s leadership will support the realisation of the full potential of our proprietary next generation TPD technology across multiple therapy areas in order to bring transformative medicines to patients.”

Amphista’s new CDO, Dr Martin Pass, commented on his appointment, “I’m delighted to join Amphista’s dynamic, world class team. Amphista is founded on transformational science and I am looking forward to driving the Company’s clinical development programmes and research as we pursue our mission of building the world’s leading TPD company and ultimately bringing benefit to patients.”

- Ends –

 

Click here for photo of Dr Martin Pass, Amphista’s Chief Development Officer.

 

Media contacts:

 

Amphista Therapeutics

CEO NicolaThompson

+447464974714

nicki@amphista.com

 

Scius Communications

Katja Stout

+447789435990

katja@sciuscommunications.com

 

About Amphista Therapeutics

Amphista Therapeutics is focused on transforming the lives of patients with severe diseases including cancer. The company is applying its proprietary Amphista degrader platform to advance new approaches in targeted protein degradation (TPD), which address the challenges faced by the field and to realise the full therapeutic potential of this transformational approach. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s labs at the University of Dundee. The company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company.

For more information, please visit: http://www.amphista.com/

 

Editor Details

Last Updated: 07-Dec-2021